XML 31 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure [Table]          
Pay vs Performance Disclosure, Table

PAY VERSUS PERFORMANCE TABLE

 

The following table sets forth information concerning the compensation of our NEOs for each of the fiscal years ended December 31, 2020, 2021, 2022, 2023, and 2024, and our financial performance for each such fiscal year:

 

(a) (b) (c) (d) (e) (f) (g) (h) (i)
          Value of Initial Fixed $100    
          Investment Based on:    
      Average          
      Summary Average        
  Summary   Compensation Compensation   Peer Group    
  Compensation Compensation Table Total for Actually Paid Total Total    
  Table Total for Actually Paid Non-CEO to Non-CEO Shareholder Shareholder   Operating
  CEO to CEO NEOs NEOs Return Return Net Income Income
Year ($) ($)(1) ($) ($)(1) ($) ($)(2) ($) ($)(3)
2024 8,289,471 8,615,470 3,140,343 3,189,259 88.78 133.07 (1,844,200,000) 269,000,000
2023 7,463,878 1,024,738 2,537,102 (2,078,375) 87.26 137.88 (637,324,000) 337,796,000
2022 7,527,985 (5,584,118) 2,613,905 (118,708) 113.64 142.26 (3,627,535,000) 482,616,000
2021 8,695,925 20,352,010 3,192,227 4,960,520 204.19 184.53 4,254,257,000 500,336,000
2020 7,992,423 21,276,674 2,825,690 4,664,567 157.54 133.01 3,814,229,000 421,326,000
(1)Amounts represent compensation actually paid to our chief executive officer (CEO) and the average compensation actually paid to our remaining NEOs for the relevant fiscal year, as determined under SEC rules (and described below), which includes the individuals indicated in the table below for each fiscal year:
(2)For the relevant fiscal year, represents the cumulative TSR (the “Peer Group TSR”) of the S&P 500 Life Sciences Tools & Services Index (the “Peer Group”).

(3)Operating Income is a GAAP measure. We selected operating income as the Company Selected Measure because, among other things, operating income is a significantly weighted measure under our cash based-incentive bonus plan.
        
Company Selected Measure Name Operating Income        
Named Executive Officers, Footnote

(1)Amounts represent compensation actually paid to our chief executive officer (CEO) and the average compensation actually paid to our remaining NEOs for the relevant fiscal year, as determined under SEC rules (and described below), which includes the individuals indicated in the table below for each fiscal year:

Year CEO Non-CEO NEOs
2024 Norman Schwartz Roop K. Lakkaraju, Jonathan P. DiVincenzo, Michael Crowley, and Eva Anette Engelhardt
2022 and 2023 Norman Schwartz Ilan Daskal, Andrew J. Last, Dara Grantham Wright, and Simon May
2021 Norman Schwartz Ilan Daskal, Andrew J. Last, Dara Grantham Wright, and Michael Crowley
2020 Norman Schwartz Ilan Daskal, Andrew J. Last, Dara Grantham Wright, and Annette Tumolo
        
Peer Group Issuers, Footnote

 

(2)For the relevant fiscal year, represents the cumulative TSR (the “Peer Group TSR”) of the S&P 500 Life Sciences Tools & Services Index (the “Peer Group”).
       
PEO Total Compensation Amount $ 8,289,471 $ 7,463,878 $ 7,527,985 $ 8,695,925 $ 7,992,423
PEO Actually Paid Compensation Amount [1] $ 8,615,470 1,024,738 (5,584,118) 20,352,010 21,276,674
Adjustment To PEO Compensation, Footnote

 

 

Compensation actually paid to our NEOs represents the “Total” compensation reported in the Summary Compensation Table for fiscal year 2024, as adjusted as follows:

 

  2024
Adjustments CEO Average Non-CEO NEOs
Deduction for Amounts Reported under the “Stock Awards” (6,837,891) (2,274,817)
and “Option Awards” Columns in the Summary    
Compensation Table for Applicable FY    
Increase based on ASC 718 Fair Value of Awards Granted 6,789,862 2,313,560
during Applicable FY that Remain Unvested as of Applicable    
FY End, determined as of Applicable FY End    
Increase/deduction for Awards Granted during Prior FYs that were 83,166 5,361
Outstanding and Unvested as of Applicable FY End,    
determined based on change in ASC 718 Fair Value from    
Prior FY End to Applicable FY End    
Increase/deduction for Awards Granted during Prior FYs that Vested 290,862 4,813
During Applicable FY, determined based on change in ASC    
718 Fair Value from Prior FY End to Vesting Date    
Deduction of ASC 718 Fair Value of Awards Granted during 0 0
Prior FY that were Forfeited during Applicable FY,    
determined as of Prior FY End    
TOTAL ADJUSTMENTS 325,999 48,916

Fair value or change in fair value, as applicable, of equity awards in the “Compensation Actually Paid” columns was determined by reference to (i) for RSU awards, the closing price per share on the applicable year-end date(s) or, in the case of vesting dates, the closing price per share on the applicable vesting date(s); (ii) for PSU awards, the same valuation methodology as RSU awards above except that the year-end values are multiplied by the probability of achievement of the applicable performance objective as of the applicable date; and (iii) for stock options, a Black Scholes value as of the applicable year-end or vesting date(s), determined based on the same methodology as used to determine grant date fair value but using the closing stock price on the applicable revaluation date as the current market price and an expected life calculated by taking the difference between the expected life as of the grant date and the time since the grant date and dividing the result by the stock-to-strike ratio as of the revaluation date. Volatility and risk-free interest rates are determined as of the revaluation date based on the expected life period. The expected dividend rate used is 0%. For PSU awards, the probability of achievement of the applicable performance objective as of December 31, 2024 was below the threshold attainment level. For additional information on the assumptions used to calculate the valuation of the awards, see the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and prior fiscal years. 

 

        
Non-PEO NEO Average Total Compensation Amount $ 3,140,343 2,537,102 2,613,905 3,192,227 2,825,690
Non-PEO NEO Average Compensation Actually Paid Amount [1] $ 3,189,259 (2,078,375) (118,708) 4,960,520 4,664,567
Adjustment to Non-PEO NEO Compensation Footnote

 

Compensation actually paid to our NEOs represents the “Total” compensation reported in the Summary Compensation Table for fiscal year 2024, as adjusted as follows:

 

  2024
Adjustments CEO Average Non-CEO NEOs
Deduction for Amounts Reported under the “Stock Awards” (6,837,891) (2,274,817)
and “Option Awards” Columns in the Summary    
Compensation Table for Applicable FY    
Increase based on ASC 718 Fair Value of Awards Granted 6,789,862 2,313,560
during Applicable FY that Remain Unvested as of Applicable    
FY End, determined as of Applicable FY End    
Increase/deduction for Awards Granted during Prior FYs that were 83,166 5,361
Outstanding and Unvested as of Applicable FY End,    
determined based on change in ASC 718 Fair Value from    
Prior FY End to Applicable FY End    
Increase/deduction for Awards Granted during Prior FYs that Vested 290,862 4,813
During Applicable FY, determined based on change in ASC    
718 Fair Value from Prior FY End to Vesting Date    
Deduction of ASC 718 Fair Value of Awards Granted during 0 0
Prior FY that were Forfeited during Applicable FY,    
determined as of Prior FY End    
TOTAL ADJUSTMENTS 325,999 48,916

Fair value or change in fair value, as applicable, of equity awards in the “Compensation Actually Paid” columns was determined by reference to (i) for RSU awards, the closing price per share on the applicable year-end date(s) or, in the case of vesting dates, the closing price per share on the applicable vesting date(s); (ii) for PSU awards, the same valuation methodology as RSU awards above except that the year-end values are multiplied by the probability of achievement of the applicable performance objective as of the applicable date; and (iii) for stock options, a Black Scholes value as of the applicable year-end or vesting date(s), determined based on the same methodology as used to determine grant date fair value but using the closing stock price on the applicable revaluation date as the current market price and an expected life calculated by taking the difference between the expected life as of the grant date and the time since the grant date and dividing the result by the stock-to-strike ratio as of the revaluation date. Volatility and risk-free interest rates are determined as of the revaluation date based on the expected life period. The expected dividend rate used is 0%. For PSU awards, the probability of achievement of the applicable performance objective as of December 31, 2024 was below the threshold attainment level. For additional information on the assumptions used to calculate the valuation of the awards, see the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and prior fiscal years. 

        
Compensation Actually Paid vs. Total Shareholder Return

Compensation Actually Paid vs. Total Shareholder Return 

 

 

        
Compensation Actually Paid vs. Net Income

Compensation Actually Paid vs. Net Income 

 

        
Compensation Actually Paid vs. Company Selected Measure

Compensation Actually Paid vs. Operating Income

 

 

        
Tabular List, Table

Pay Versus Performance Tabular List

 

We believe the following performance measures represent the most important financial performance measures used by us to link compensation actually paid to our NEOs for the fiscal year ended December 31, 2024:

 

●Operating Income; and

●Sales.

 

For additional details regarding our most important financial performance measures, please see the sections titled “Incentive Bonus Plan, or IBP (Cash-Based Incentive Program)” and “Equity Compensation” in our Compensation Discussion and Analysis (CD&A) elsewhere in this Proxy Statement.

        
Total Shareholder Return Amount $ 88.78 87.26 113.64 204.19 157.54
Peer Group Total Shareholder Return Amount [2] 133.07 137.88 142.26 184.53 133.01
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $ (1,844,200,000) $ (637,324,000) $ (3,627,535,000) $ 4,254,257,000 $ 3,814,229,000
Company Selected Measure Amount [3] 269,000,000 337,796,000 482,616,000 500,336,000 421,326,000
PEO Name Norman Schwartz Norman Schwartz Norman Schwartz Norman Schwartz Norman Schwartz
Measure [Axis]: 1          
Pay vs Performance Disclosure [Table]          
Measure Name Operating Income        
Non-GAAP Measure Description

(3)Operating Income is a GAAP measure. We selected operating income as the Company Selected Measure because, among other things, operating income is a significantly weighted measure under our cash based-incentive bonus plan.
        
Measure [Axis]: 2          
Pay vs Performance Disclosure [Table]          
Measure Name Sales        
PEO [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount $ (6,837,891)        
PEO [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount 6,789,862        
PEO [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount 83,166        
PEO [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount 290,862        
PEO [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount 0        
PEO [Member] | Equity Awards Adjustments [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount 325,999        
Non-PEO NEO [Member] | Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount (2,274,817)        
Non-PEO NEO [Member] | Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount 2,313,560        
Non-PEO NEO [Member] | Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount 5,361        
Non-PEO NEO [Member] | Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount 4,813        
Non-PEO NEO [Member] | Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount 0        
Non-PEO NEO [Member] | Equity Awards Adjustments [Member]          
Pay vs Performance Disclosure [Table]          
Adjustment to Compensation Amount $ 48,916        
[1] Amounts represent compensation actually paid to our chief executive officer (CEO) and the average compensation actually paid to our remaining NEOs for the relevant fiscal year, as determined under SEC rules (and described below), which includes the individuals indicated in the table below for each fiscal year:
[2] For the relevant fiscal year, represents the cumulative TSR (the “Peer Group TSR”) of the S&P 500 Life Sciences Tools & Services Index (the “Peer Group”).
[3] Operating Income is a GAAP measure. We selected operating income as the Company Selected Measure because, among other things, operating income is a significantly weighted measure under our cash based-incentive bonus plan.